Sonova Holding AG stock (CH0012549785): UBS trims target as hearing aid demand stays in focus

Sonova shares are back in the spotlight after UBS lowered its price target and the company’s latest earnings call pointed to a strong full-year 2025-2026 performance.

Sonova Holding AG is drawing fresh attention after UBS lowered its price target on the stock, while the company’s latest earnings discussion pointed to a strong 2025-2026 year. For U.S. investors, the name matters because Sonova sells hearing care solutions in the United States and other major markets, tying its results to global health-care demand.

The stock was trading around CHF 203 on May 20, 2026, after rising 1.5% that day, according to a market snapshot from StockInvest.us as of 05/20/2026. UBS also cut its target on Sonova to CHF 206 from CHF 215 while keeping a neutral stance, according to Zonebourse as of 05/22/2026. Separately, an earnings-call transcript said Sonova delivered strong results in the 2025-2026 year and outperformed expectations, according to Investing.com as of 05/22/2026.

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Sonova Holding AG
• Sector/industry: Health care equipment
• Headquarters/country: Switzerland
• Core markets: United States, Europe, the Americas, and other international regions
• Key revenue drivers: Hearing aids, cochlear implants, and related hearing-care services
• Home exchange/listing venue: SIX Swiss Exchange (SOON)
• Trading currency: CHF

Sonova Holding AG: core business model

Sonova is a hearing-care group with brands and products aimed at people with hearing loss, spanning fitting, accessories, and broader care services. The company’s geographic mix gives it exposure to consumer health spending and reimbursement trends in several regions, including the U.S. market.

The latest company commentary highlighted a strong 2025-2026 performance, which is relevant because hearing care is a recurring-demand business rather than a one-time device sale. That can help support visibility, but it also means results can be sensitive to clinic traffic, pricing, and changes in patient demand.

Main revenue and product drivers for Sonova Holding AG

Sonova’s revenue drivers are centered on hearing aids and related solutions, which are sold through a mix of professional and retail channels. The company’s U.S. exposure matters because the American market is one of the largest and most competitive in global hearing care.

For investors, the key question is whether recent operational strength can offset valuation pressure after UBS trimmed its price target. The market reaction in Zurich suggests shares remain responsive to both fundamentals and broker sentiment, even when the underlying business mix has not changed materially.

Why Sonova Holding AG matters for US investors

Sonova matters to U.S. investors because part of its business is tied to American demand for hearing-care products and services. That makes the stock relevant not only as a Swiss health-care name, but also as a company with direct exposure to U.S. consumer and medical spending.

The recent broker note from UBS adds a valuation angle, while the earnings-call commentary adds a business-performance angle. Together, they create a simple but important setup: a company with a global franchise, but one that can still see meaningful share-price reactions to changes in expectations.

Conclusion

Sonova is not being driven by a single event, but by a combination of broker sentiment and recent operating commentary. The stock’s move in Zurich and UBS’s lower target show that investors are still weighing growth durability against valuation. For U.S. readers, the key takeaway is that Sonova has real exposure to the American hearing-care market, which can make its results relevant beyond Switzerland. The next catalyst will likely come from how the market interprets demand trends, margins, and any further guidance updates.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.